All In Biotech

NDA 211415 · Esteve

Quzyttir

Cetirizine Hydrochloride · Intravenous

Last checked: Nov 20, 2026Latest source record: Jul 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Oct 4, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

134

35 Phase 3, 7 recruiting

FAERS reports

31,397

24,248 serious, 5,131 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 22, 2026.

QUZYTTIR ® is indicated for the treatment of acute urticaria in adults and children 6 months of age and older. QUZYTTIR ® is a histamine-1 (H 1 ) receptor antagonist indicated for the treatment of acute urticaria in adults and children 6 months of age and older ( 1 ) Limitations of Use : Not recommended in pediatric patients less than 6 years of age with impaired renal or hepatic function ( 1 ) Limitations of use: QUZYTTIR ® is not recommended in pediatric patients less than 6 years of age with impaired renal or hepatic function.

Mechanism: Cetirizine hydrochloride, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of peripheral H 1 -receptors. The antihistaminic activity of cetirizine hydrochloride has been clearly documented in a variety of animal and human models. In vivo and ex vivo animal models have shown negligible anticholinergic and antiserotonergic activity. In clinical studies however, dry mouth was more common with cetirizine hydrochloride than with placebo. In vitro receptor binding studies have shown no measurable affinity for receptors other than H...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • QUZYTTIR · CETIRIZINE HYDROCHLORIDE 10MG/ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cetirizine" as an intervention, any sponsor and status, largest first.

All 134 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective9,563
  • pain8,983
  • fatigue8,946
  • alopecia7,541
  • rheumatoid arthritis7,475
  • abdominal discomfort7,448
  • systemic lupus erythematosus7,162
  • pemphigus7,032
  • off label use6,781
  • rash6,691
  • glossodynia6,533
  • swelling6,091

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200419
200560
200620
200766
2008169
2009159
2010137
2011137
2012159
2013208
2014240
2015359
2016814
2017874
20181,009
20191,555
20202,155
20214,402
20224,406
20233,425
20244,299
20254,038
20262,687

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Quzyttir (Cetirizine HCl)

2024 spending

$638K

Beneficiaries

12

216 claims

Per beneficiary

$53,205

$316.23 per unit

View as table
YearSpending
2020$0
2021$176,810
2022$442,545
2023$615,775
2024$638,459

Part B: Quzyttir (Cetirizine HCL) · HCPCS J1201

2024 spending

$967K

Beneficiaries

852

3,198 claims

Per beneficiary

$1,135

2024 ASP limit $14.97 per unit

View as table
YearSpending
2020$42,271
2021$135,504
2022$182,775
2023$547,955
2024$966,713

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 531 on PubMed

Sponsor: Esteve

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.